Medical technology Straumann generates higher sales in the third quarter - EMEA region drives growth
Straumann's sales increased further in the third quarter. The dental implant business performed particularly well, especially in regions such as EMEA. The Group confirms its 2025 outlook.
29.10.2025, 07:34
SDA
Between July and September, Straumann generated sales of CHF 602.2 million, an increase of 2.9 percent. In organic terms, i.e. excluding acquisitions and currency effects, growth would have amounted to +8.3 percent (previous year: 9.6 percent), as detailed in a press release issued on Wednesday. Straumann traditionally does not publish profit figures for odd-numbered quarters.
Due to the sometimes significant differences, there has recently been an increased focus on regional sales. Revenue in the most important region, Europe, Middle East & Africa, rose by 8.2 percent to 234 million in the third quarter. In North America, however, revenue fell by 0.8%. Asia recorded a decline of 3.4 percent, while Straumann's sales in Latin America were up 9.8 percent.
According to Straumann, a sequential improvement was observed in North America. However, the Asia-Pacific region is also in the spotlight. Growth outside of China remained solid here. Meanwhile, growth in China was weaker than expected. "This was due to more cautious patient demand and inventory reductions by distributors ahead of the expected introduction of VBP 2.0 - the second phase of volume-based public procurement, which is due to be implemented at the beginning of next year."
Outlook confirmed
Straumann confirms its previous outlook for the further course of business. Accordingly, the company is aiming for organic sales growth in the high single-digit percentage range for 2025 as a whole. At profit level, Straumann's forecast is based on core operating profit (core EBIT), which is adjusted for items such as amortization from purchase price allocation, impairment losses, restructuring costs, etc. The company is still aiming for a margin at constant exchange rates that is 30 to 60 basis points above the 2024 figure of 26.0 percent. In the first half of the year, Straumann reported a figure of 26.6 percent.
As Straumann further writes, macroeconomic and regulatory challenges - including exchange rate volatility and customs duties - are expected to persist.
As Straumann announced separately this morning, strategic changes are being made. In order to strengthen its competitiveness in the field of transparent dental splints, the Group is transforming its orthodontics business through strategic partnerships with Smartee and DentalMonitoring, for example.
